Based on a rotary platform with disposable, individualised reactors, the Tetras is designed to have significant advantages over older designs
Thuramed has announced the launch of its new multiple-peptide robotic synthesizer, the Tetras.
Based on a rotary platform with disposable, individualised reactors, the Tetras is designed to have significant advantages over older designs including: reduced contamination, increased speed and improved ease of use.
Bryan Jones, Thuramed sales manager said, "The Tetras is a totally new approach to multiple peptide synthesis.
"Arguably, this is the first major innovation in robotic synthesis in nearly 20 years.
"It should also work well for DNA synthesis.
Thuramed is a subsidiary of CreoSalus.
Other CreoSalus companies include Advanced ChemTech and Thorn BioScience.
